Iqirvo PBC denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Iqirvo (Elafibranor) for PBC on Medical-Necessity Grounds

Aetna's medical-necessity denials for Iqirvo in primary biliary cholangitis (PBC) typically reflect a determination that the submitted clinical record does not clearly establish that the drug meets Aetna's internally defined criteria for coverage — most often because the documentation of disease severity, prior treatment history, or inadequate response to first-line therapy is incomplete or ambiguous.

This denial is appealable. PBC is a progressive, potentially life-threatening autoimmune liver disease, and Iqirvo holds FDA approval specifically for this indication. That regulatory approval is itself strong evidence of medical necessity for appropriately selected patients.

## Your Federal Appeal Rights

• ERISA §503 (employer-sponsored plans): Entitles you to a full-and-fair review. Internal appeal must be decided within 60 days (non-urgent) or 72 hours (urgent/expedited).
• ACA §2719 external review: After exhausting internal appeals, you may request an independent external review through your state insurance commissioner or a federally-contracted IRO. The external-review window is generally four months from the denial notice. Expedited external review is available when your health is at serious risk.
• State insurance department: File a complaint in parallel — regulators can apply pressure and track insurer behavior.

## Concrete Appeal Steps

1. Request the full Explanation of Benefits and Aetna's written denial letter with the specific criteria not met. 2. Request Aetna's Medical Policy for Iqirvo or elafibranor so you can see the exact requirements you must address. 3. Have your prescriber draft a detailed medical-necessity letter. 4. Compile your documentation package (see below). 5. Submit your internal appeal, citing the denial criteria point by point. 6. If denied again, file for external review immediately.

## Documentation to Gather

• Confirmed PBC diagnosis: Liver biopsy report, AMA (anti-mitochondrial antibody) lab results, and hepatologist or gastroenterologist consultation notes confirming the diagnosis.
• Disease severity: Recent liver function tests, liver stiffness or imaging studies, and MELD or Child-Pugh scoring in your chart — whatever your physician uses to characterize severity.
• Prior treatment history: Records showing dates started, doses, duration, and outcomes for prior PBC-indicated therapies. Document specifically why each was inadequate — whether due to intolerance, contraindication per your physician's judgment, or insufficient biochemical response.
• Prescriber medical-necessity letter: Should explain why Iqirvo is the appropriate next step for your specific clinical situation, referencing applicable guidelines from the relevant hepatology society.
• FDA prescribing label: Reference the approved indication; confirm your diagnosis meets it exactly.

## Criteria-Mapping Structure

Obtain Aetna's current Medical Policy and the FDA-approved prescribing information for Iqirvo. For each criterion listed in both documents, create a two-column table:

| Policy/Label Requirement | Supporting Chart Evidence | |---|---| | [Paste each requirement verbatim] | [Exact note, date, lab result, or prescriber statement that satisfies it] |

This structured mapping forces the reviewer to engage with your evidence criterion by criterion and leaves no gap unaddressed.